Transgene

Transgene FCF Margin

The Free Cash Flow Margin of Transgene (TNG.PA) as of Sep 30, 2026 is -437.66 %. In the previous year, Free Cash Flow Margin was -489.10 % — a change of -10.52% (higher).

FCF Margin

-437.66 %

YoY

-10.52%

Last updated:

Free Cash Flow Margin of Transgene is 2026 -437.66 % . Free Cash Flow Margin of Transgene was 2025 -489.10 % . It decreases by -10.52% higher compared to the previous year.

The Transgene FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2017
-480.11 EUR
Jan 1, 2018
-419.82 EUR
Jan 1, 2019
-181.27 EUR
Jan 1, 2020
-316.31 EUR
Jan 1, 2021
-156.22 EUR
Jan 1, 2022
-217.96 EUR
Jan 1, 2023
-489.10 EUR
Jan 1, 2024
-437.66 EUR
The Transgene FCF Margin history
YEARFCF MarginYoY
-437.66 %-10.52%
-489.10 %+124.40%
-217.96 %+39.52%
-156.22 %-50.61%
-316.31 %+74.50%
-181.27 %-56.82%
-419.82 %-12.56%
-480.11 %+24.67%
-385.11 %-21.09%
-488.02 %-4.47%
-510.85 %—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Free Cash Flow Margin of Transgene is -437.66 % in 2026.

Free Cash Flow Margin of Transgene changed from -489.10 % to -437.66 %, representing a -10.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Transgene since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Transgene

All Key Metrics — Transgene